Mizuho Securities USA LLC Has $10.91 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mizuho Securities USA LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 46.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 118,118 shares of the biopharmaceutical company's stock after acquiring an additional 37,387 shares during the period. Mizuho Securities USA LLC's holdings in Gilead Sciences were worth $10,911,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership bought a new position in Gilead Sciences in the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences in the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC increased its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.16% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have weighed in on GILD shares. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. BMO Capital Markets boosted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. The Goldman Sachs Group upped their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $104.52.

Gilead Sciences Stock Up 1.3 %

Shares of Gilead Sciences stock traded up $1.38 on Wednesday, hitting $109.27. 7,391,019 shares of the company traded hands, compared to its average volume of 6,810,706. The company has a 50-day moving average price of $104.35 and a 200 day moving average price of $94.36. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a market cap of $136.08 billion, a PE ratio of 295.32, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.89%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.